Cardiology Involvement in Patients with Breast Cancer Treated with Trastuzumab.

ABSTRACT:

Background

There is limited evidence regarding the impact of cardiology involvement in the care of cancer patients.

Objectives

We evaluated the impact of cardiology involvement on guideline-adherent cardiovascular monitoring and risk factor management in breast cancer patients treated with trastuzumab.

Methods

In a single-center retrospective cohort study, we evaluated electronic health records from 1,047 breast cancer patients receiving trastuzumab between January 2009 and July 2018. A visit to a cardiology provider beginning from the 3 months prior to cancer therapy initiation until the last contact date defined cardiology involvement. Guideline-adherent monitoring, defined by echocardiography assessment within the 4 months prior to trastuzumab initiation and follow

SUBMITTER: Demissei BG 

PROVIDER: S-EPMC7701353 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature